Aspire Submits Registration Statement for US IPO

Feb.22.2023
Aspire Submits Registration Statement for US IPO
Aspire, an e-cigarette and CBD product company, submitted registration to list on NASDAQ with an expected $155.25 million in funding.

On February 20th, the electronic cigarette and CBD product company, Aspire, filed a registration statement to go public on the US stock market.


The company intends to go public on the NASDAQ stock exchange, with a proposed maximum share price of $9 and the aim of raising $155.25 million by issuing 17.25 million shares. The registration statement provides details on the company's current operations, risk factors, and equity structure.


The parent company of Aspire, a business department, is a manufacturer of vape and CBD products. The total global retail sales of vape products from 2015 to 2020 and the retail sales forecast for 2021 to 2024 are also presented in the registration document (see chart below).


Source: US Securities and Exchange Commission


According to data, during the early days of the company's establishment (2015-17), an open system was more welcomed by the market. However, since the gradual replacement of open vaping systems with closed ones, closed systems have become the mainstream in the market and surpassed open systems in 2019. That year, the global sales of closed vaping systems reached $9.688 billion, surpassing open systems' $8.392 billion.


The company predicts that closed systems will continue to dominate the market and that global vape sales will reach $66.8 billion by 2023.


Since 2019, the company has been expanding its CBD market in the United States and Canada. In 2020, the global sales of cannabis products reached $2.9 billion.


Source: U.S. Securities and Exchange Commission


In addition, the company also undertakes OEM/ODM business for electronic atomization systems.


According to Aspire's registration document, the company's main market is Europe, with the European market accounting for 61% of the company's total performance in 2020, followed by 22.6% in the United States. Their efforts to expand in the Asia-Pacific market have been significant, increasing from 0.1% in 2019 to 9.5%.


Source: U.S. Securities and Exchange Commission.


The risk factors listed in the registration statement of the company are as follows:


Existing and newly enacted laws, regulations, and policies could present barriers to the company's future business operations and have significant adverse effects. Currently, the company can only legally sell one product, Nautilus Prime, in the US, which accounted for less than 11% of the company's US revenues in the year ending June 30, 2020. As a result, the company can no longer sell products that accounted for more than 89% of their US revenues in that same period, leading to a decline in US sales in the six months ending December 31, 2020. The market for cannabis vaporization products is still immature, with most sales occurring in the US, and expansion in the US or globally is not guaranteed. Recently, joint statements from the US Securities and Exchange Commission and the Public Company Accounting Oversight Board, proposed rule changes from NASDAQ, and a bill passed by the US Senate have all called for stricter standards when evaluating the qualifications of auditors for emerging market companies, especially those auditors that are not subject to PCAOB inspections outside of the US. These developments could increase uncertainty around the company's issuances. If there is evidence to suggest or research to show that the use of electronic vaporization or cannabis products poses long-term health risks, the use of such products could significantly decrease, which would have a substantial adverse impact on the company's business, financial condition, and operating performance. The company's operations entail inherent risks and uncertainties, including developments in regulatory environments, medical discoveries, and the market's acceptance of electronic cigarette devices. The company faces potential adverse effects due to sales, product liability, and user complaints. Misuse or abuse of the company's products could lead to potential adverse health effects, leading to complaints, product liability claims, and negative publicity. The company faces competition in the electronic vaporization industry, including larger, more well-known companies with a significantly larger market share, and Aspire may not effectively compete. In addition, widespread outbreaks of diseases, natural disasters, or improper behavior by employees or distributors could harm the company's interests and reputation and have an adverse impact on its business operations.


2FIRSTS will continue to follow this topic and provide timely updates. Stay tuned for our latest coverage.


Reference:


Aspire has filed a registration statement with the U.S. Securities and Exchange Commission.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

Imperial Brands' NGP Revenue Rises 11.4% in FY2026 but Business Still Posts £63 Million Loss; Zone Reaches 114,000 US Stores as Smokeless Reporting Takes Shape
Imperial Brands' NGP Revenue Rises 11.4% in FY2026 but Business Still Posts £63 Million Loss; Zone Reaches 114,000 US Stores as Smokeless Reporting Takes Shape
Imperial Brands reported an 11.4% increase in next-generation product (NGP) net revenue to £419 million in fiscal 2026, while its adjusted NGP operating loss narrowed to £63 million. European NGP revenue rose 16.8%, while the Americas recorded a 17.1% decline. Global modern oral nicotine volumes increased 27.8%, with US nicotine pouch brand Zone expanding to approximately 114,000 stores. The company also acquired Black Buffalo in the US and Helwit in Sweden, broadening its oral nicotine portfolio. From FY2027, Imperial Brands will adopt a new Smokeless reporting category combining NGP with traditional oral tobacco. On the new basis, FY2026 Smokeless net revenue was £554 million, with adjusted operating profit of £14 million.
company
Nov.18
IKE Tech Launches IKE 2.0 Compliance Platform for Nicotine Products
IKE Tech Launches IKE 2.0 Compliance Platform for Nicotine Products
IKE Tech launched IKE 2.0 on September 28, initially targeting nicotine products with a platform that combines user identity verification, product authentication, configurable policy controls and data analytics. Products can be authenticated through direct device integration or NFC smart tags. IKE Tech was formed with participation from Ispire's Aspire North America, Berify and Chemular, with Ispire currently holding a 40% interest. Its age-verification component PMTA was accepted by the FDA in 2025 and remains under review. The company did not disclose customer names, commercial deployment volumes, pricing or revenue tied to IKE 2.0.
News
Sep.29 by 2Firsts Perspectives
Russia's State Duma Passes Tobacco and Nicotine Ingredient Disclosure Bill, Targeting 2027 End to Trade-Secret Protection for Certain Harmful Ingredient Data
Russia's State Duma Passes Tobacco and Nicotine Ingredient Disclosure Bill, Targeting 2027 End to Trade-Secret Protection for Certain Harmful Ingredient Data
Russia's State Duma passed a government-sponsored amendment on November 11, 2026, by 414 votes to none, seeking to prevent businesses from classifying information on the presence and number of types of certain harmful ingredients in tobacco and nicotine-containing products as trade secrets. The measure covers ingredients capable of increasing nicotine dependence or exhibiting toxic, carcinogenic, mutagenic or reproductive toxicity, including substances that acquire such properties during heating or smoldering. Bill No. 1286415-8 would amend Article 5 of Federal Law No. 98-FZ on Commercial Secrets and is scheduled to take effect on January 1, 2027. The bill has cleared all three readings in the State Duma but has not completed the remaining legislative procedures.
Regulations
Nov.12 by 2Firsts Perspectives
On-Site Report | After FDA Announces Review of PMTA Framework, CTP Director Details Reform Priorities
On-Site Report | After FDA Announces Review of PMTA Framework, CTP Director Details Reform Priorities
FDA CTP Director Bret Koplow used his FDLI keynote in Washington to outline how the agency is rethinking the PMTA framework. He discussed category-specific review, nicotine pouch and sPMTA pilots, AI-assisted review, a 70% reduction in pending applications, and a major staffing constraint: CTP currently has only nine scientific review teams. He also reaffirmed tobacco harm reduction while stressing youth protection, flavored products, risk communication, and the challenge of unauthorized e-cigarettes.
Regulations
Oct.06
FDA Appoints Former Tobacco Enforcement Deputy Jessica Zeller as Director as Agency Weighs PMTA Framework Changes
FDA Appoints Former Tobacco Enforcement Deputy Jessica Zeller as Director as Agency Weighs PMTA Framework Changes
The U.S. Food and Drug Administration (FDA) has named Jessica Zeller director of the Center for Tobacco Products' (CTP) Office of Compliance and Enforcement (OCE), effective November 1, 2026. Zeller, the office's inaugural deputy director, returns from medical device manufacturer Edwards Lifesciences with more than 20 years of regulatory and legal experience. The appointment follows CTP leadership changes and adjustments to tobacco regulation. Bret Koplow became permanent CTP director in September; the FDA revised enforcement priorities for unauthorized e-cigarettes and nicotine pouches in May and announced faster PMTA review procedures. On September 28, the agency said it would evaluate changes to the existing PMTA regulatory framework, including potential rulemaking to replace it.
FDA
Oct.20 by 2Firsts Perspectives
Special Report | From New York to Washington: How FDA’s Tobacco Center Is Reworking Product Review
Special Report | From New York to Washington: How FDA’s Tobacco Center Is Reworking Product Review
FDA’s Center for Tobacco Products is reshaping how it approaches tobacco product review. Based on 2Firsts’ on-site reporting in New York and Washington, this report traces CTP’s emerging direction: stronger links between PMTA and tobacco harm reduction, more category-specific review, greater emphasis on decision-relevant science, more predictable timelines and expanded use of sPMTA for product modifications. CTP also acknowledged major constraints, including just nine PMTA review teams, persistent backlogs and limits on hiring capacity.
Regulations
Oct.08